# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001438533-26-000027
Filing Date
2026-04-06
Accepted
2026-04-06 16:07:43
Documents
18
Period of Report
2026-05-19

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tvtx-20260404.htm iXBRL | DEF 14A | 1441765
3 | GRAPHIC | tvtx-20260404_g1.jpg | GRAPHIC | 300529
4 | GRAPHIC | tvtx-20260404_g2.jpg | GRAPHIC | 254659
5 | GRAPHIC | tvtx-20260404_g3.jpg | GRAPHIC | 242799
6 | GRAPHIC | tvtx-20260404_g4.jpg | GRAPHIC | 1020
7 | GRAPHIC | tvtx-20260404_g5.jpg | GRAPHIC | 915
8 | GRAPHIC | tvtx-20260404_g6.jpg | GRAPHIC | 889
| Complete submission text file | 0001438533-26-000027.txt |  | 4133291

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | tvtx-20260404.xsd | EX-101.SCH | 922
21 | EXTRACTED XBRL INSTANCE DOCUMENT | tvtx-20260404_htm.xml | XML | 147667

Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36257 | Film No.: 26841245
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)